 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of [0m
[34mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of [0m
[32mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"AMBISOME"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: AMBISOME: clinical_studies: The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no [0m
[31mprior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy [0m[1;31m([0m[31mEOT[0m[1;31m)[0m[31m and as overall success [0m[1;31m([0m[31mclearance with no [0m
[31mrelapse[0m[1;31m)[0m[31m during the follow-up period [0m[1;31m([0m[31mF/U[0m[1;31m)[0m[31m of greater than [0m[1;31m6[0m[31m months for immunocompetent and immunocompromised patients: AmBisome Efficacy in Visceral Leishmaniasis Immunocompetent Patients No. of [0m
[31mPatients Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m[1;31m87[0m[31m [0m[1;31m86[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m98.9[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m96.5[0m[1;31m)[0m[31m Immunocompromised Patients Regimen Total Dose Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m
[1;31m100[0m[31m mg/day X [0m[1;31m21[0m[31m days [0m[1;31m29[0m[31m-[0m[1;31m38[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m mg/kg [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m20[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m mg/kg/day, days [0m[1;31m1[0m[31m-[0m[1;31m5[0m[31m, and [0m[1;31m10[0m[31m, [0m[1;31m17[0m[31m, [0m[1;31m24[0m[31m, [0m[1;31m31[0m[31m, [0m[1;31m38[0m[31m [0m[1;31m40[0m[31m mg/kg [0m[1;31m8[0m[31m/[0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m88.9[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m/[0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m TOTAL [0m[1;31m18[0m[31m/[0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m94.7[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m11.8[0m[1;31m)[0m[31m When [0m
[31mfollowed for [0m[1;31m6[0m[31m months or more after treatment, the overall success rate among immunocompetent patients was [0m[1;31m96.5[0m[31m% and the overall success rate among immunocompromised patients was [0m[1;31m11.8[0m[31m% due to relapse [0m
[31min the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients [0m[1;31m([0m[31mLopez-Dupla, et al. AMBISOME: clinical_studies:[0m
[31mJ Antimicrob Chemother [0m[1;31m1993[0m[31m; [0m[1;31m32[0m[31m: [0m[1;31m657[0m[31m-[0m[1;31m659[0m[1;31m)[0m[31m, there are no data to date documenting the efficacy or safety of repeat courses of Am B isome or of maintenance therapy with this drug among immunocompromised[0m
[31mpatients.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m Fever resolution during neutropenic period [0m[1;31m199[0m[31m [0m[1;31m([0m[1;31m58[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m([0m[1;31m58.1[0m[31m%[0m[1;31m)[0m[31m No treatment-emergent fungal infection [0m[1;31m300[0m[31m [0m[1;31m([0m[1;31m87.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m301[0m[31m [0m[1;31m([0m[1;31m87.7[0m[31m%[0m[1;31m)[0m[31m Survival through [0m[1;31m7[0m[31m days post [0m
[31mstudy drug [0m[1;31m318[0m[31m [0m[1;31m([0m[1;31m92.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m308[0m[31m [0m[1;31m([0m[1;31m89.5[0m[31m%[0m[1;31m)[0m[31m Study drug not prematurely discontinued due to toxicity or lack of efficacy* [0m[1;31m294[0m[31m [0m[1;31m([0m[1;31m85.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m280[0m[31m [0m[1;31m([0m[1;31m81.4[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m8[0m[31m and [0m[1;31m10[0m[31m patients, respectively, were treated as failures due [0m
[31mto premature discontinuation alone. This therapeutic equivalence had no apparent relationship to the use of prestudy antifungal prophylaxis or concomitant granulocytic colony-stimulating factors. The [0m
[31mincidence of mycologically-confirmed, and clinically-diagnosed, emergent fungal infections are presented in the following table. Am B isome and amphotericin B were found to be equivalent with respect [0m
[31mto the total number of emergent fungal infections. AMBISOME: clinical_studies: Empirical Therapy in Febrile Neutropenic Patients: Emergent Fungal Infections AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m [0m
[31mmg/kg/day Number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Mycologically-confirmed fungal infection [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m3.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m27[0m[31m [0m[1;31m([0m[1;31m7.8[0m[31m%[0m[1;31m)[0m[31m Clinically-diagnosed fungal infection [0m[1;31m32[0m[31m [0m[1;31m([0m[1;31m9.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTotal emergent fungal infections [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m Mycologically-confirmed fungal infections at study entry were cured in [0m[1;31m8[0m[31m of [0m[1;31m11[0m[31m patients in the Am B isome group and [0m[1;31m7[0m[31m of [0m[1;31m10[0m[31m in the amphotericin B[0m
[31mgroup. AMBISOME: clinical_studies: Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a randomized, double-blind, comparative multi-center trial, evaluated the safety of Am B isome [0m[1;31m([0m[1;31m3[0m[31m and [0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m compared with amphotericin B lipid[0m
[31mcomplex [0m[1;31m([0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m in the empirical treatment of [0m[1;31m202[0m[31m adult and [0m[1;31m42[0m[31m pediatric neutropenic patients. One hundred and sixty-six [0m[1;31m([0m[1;31m166[0m[1;31m)[0m[31m patients received Am B isome [0m[1;31m([0m[1;31m85[0m[31m patients received [0m[1;31m3[0m[31m mg/kg/day and [0m
[1;31m81[0m[31m received [0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m and [0m[1;31m78[0m[31m patients received amphotericin B lipid complex. The study patients were febrile despite having received at least [0m[1;31m72[0m[31m hours of broad spectrum antibacterial therapy. The [0m
[31mprimary endpoint of this study was safety. The study was not designed to draw statistically meaningful conclusions related to comparative efficacy and, in fact, Abelcet is not labeled for this [0m
[31mindication. AMBISOME: clinical_studies: Two supportive, prospective, randomized, open-label, comparative multi-center studies examined the efficacy of two dosages of Am B isome [0m[1;31m([0m[1;31m1[0m[31m and [0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m [0m
[31mcompared to amphotericin B deoxycholate [0m[1;31m([0m[1;31m1[0m[31m mg/kg/day[0m[1;31m)[0m[31m in the treatment of neutropenic patients with presumed fungal infections. These patients were undergoing chemotherapy as part of a bone marrow [0m
[31mtransplant or had hematological disease. Study [0m[1;31m104[0m[31m-[0m[1;31m10[0m[31m enrolled adult patients [0m[1;31m([0m[31mn = [0m[1;31m134[0m[1;31m)[0m[31m. Study [0m[1;31m104[0m[31m-[0m[1;31m14[0m[31m enrolled pediatric patients [0m[1;31m([0m[31mn = [0m[1;31m214[0m[1;31m)[0m[31m. Both studies support the efficacy equivalence of Am B isome[0m
[31mand amphotericin B as empirical therapy in febrile neutropenic patients. AMBISOME: clinical_studies: Treatment of Cryptococcal Meningitis in HIV-Infected Patients Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, [0m
[31mdouble-blind, comparative multi-center trial, evaluated the efficacy of Am B isome at doses [0m[1;31m([0m[1;31m3[0m[31m and [0m[1;31m6[0m[31m mg/kg/day[0m[1;31m)[0m[31m compared with amphotericin B deoxycholate [0m[1;31m([0m[1;31m0.7[0m[31m mg/kg/day[0m[1;31m)[0m[31m for the treatment of [0m
[31mcryptococcal meningitis in [0m[1;31m266[0m[31m adult and one pediatric HIV-positive patients [0m[1;31m([0m[31mthe pediatric patient received amphotericin B deoxycholate[0m[1;31m)[0m[31m. Of the [0m[1;31m267[0m[31m treated patients, [0m[1;31m86[0m[31m received Am B isome [0m[1;31m3[0m[31m [0m
[31mmg/kg/day, [0m[1;31m94[0m[31m received [0m[1;31m6[0m[31m mg/kg/day and [0m[1;31m87[0m[31m received amphotericin B deoxycholate; cryptococcal meningitis was documented by a positive CSF culture at baseline in [0m[1;31m73[0m[31m, [0m[1;31m85[0m[31m and [0m[1;31m76[0m[31m patients, respectively. [0m
[31mPatients received study drug once daily for an induction period of [0m[1;31m11[0m[31m to [0m[1;31m21[0m[31m days.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m57.7[0m[31m%[0m[1;31m)[0m[31m Nausea [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m10.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m9.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m Vomiting [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m5.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m15.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTachycardia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m17.9[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m10.3[0m[31m%[0m[1;31m)[0m[31m Hypoxia [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m Day [0m[1;31m1[0m[31m body temperature increased [0m
[31mabove the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest infusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. Patients were not administered [0m
[31mpremedications to prevent infusion-related reactions prior to the Day [0m[1;31m1[0m[31m study drug infusion. In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, double-blind, multicenter trial comparing Am B isome and amphotericin B [0m
[31mdeoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted. Am B isome-treated patients had a lower incidence of fever, [0m
[31mchills/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. [0m
[31mAMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Patients with fever increase of >[0m[1;31m1[0m[31m°C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mchills/rigors [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m42[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m Respiratory adverse events [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m There have been a few [0m
[31mreports of flushing, back pain with or without chest tightness, and chest pain associated with Am B isome administration; on occasion this has been severe. Where these symptoms were noted, the [0m
[31mreaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. AMBISOME: adverse_reactions: The symptoms do not occur with every dose and [0m
[31musually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a significantly lower incidence of grade [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m toxicity [0m
[31mwas observed in the Am B isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity [0m
[31mor discontinuation of study drug due to an infusion-related reaction compared with those administered Am B isome. In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a greater proportion of patients in the [0m
[31mamphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am B isome groups. AMBISOME: adverse_reactions: Less Common Adverse Events The following adverse [0m
[31mevents also have been reported in [0m[1;31m2[0m[31m% to [0m[1;31m10[0m[31m% of Am B isome-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a [0m
[31mWhole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular [0m
[31mSystem Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: Am B isome-treated patients had a lower incidence of infusion-related fever [0m[1;31m([0m[1;31m17[0m[31m% versus [0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m, chills/rigors [0m[1;31m([0m[1;31m18[0m[31m% versus [0m[1;31m54[0m[31m%[0m[1;31m)[0m[31m and vomiting [0m[1;31m([0m[1;31m6[0m[31m% versus [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m on Day [0m[1;31m1[0m[31m [0m
[31mas compared to amphotericin B deoxycholate-treated patients. The incidence of infusion-related reactions on Day [0m[1;31m1[0m[31m in pediatric and adult patients is summarized in the following table: Incidence of Day[0m
[1;31m1[0m[31m Infusion-Related Reactions [0m[1;31m([0m[31mIRR[0m[1;31m)[0m[31m By Patient Age Pediatric Patients [0m[1;31m([0m[31m≤ [0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m Adult Patients [0m[1;31m([0m[31m> [0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day AmBisome [0m[1;31m3[0m[31m mg/kg/day [0m
[31mAmphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m48[0m[31m [0m[1;31m47[0m[31m [0m[1;31m295[0m[31m [0m[1;31m297[0m[31m Patients with fever* increase ≥ [0m[1;31m1[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m0[0m[31m o C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m47[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m
[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m128[0m[31m [0m[1;31m([0m[1;31m43[0m[31m%[0m[1;31m)[0m[31m Patients with chills/rigors [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m47[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m59[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m165[0m[31m [0m[1;31m([0m[1;31m56[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m38[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m31[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m21[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mother reactions [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m47[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m23[0m[31m%[0m[1;31m)[0m[31m * Day [0m[1;31m1[0m[31m body temperature increased above the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest [0m
[31minfusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. AMBISOME: adverse_reactions: Cardiorespiratory events, except for vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m, during all study drug infusions were more frequent in[0m
[31mamphotericin B-treated patients as summarized in the following table: Incidence of Infusion-Related Cardiorespiratory Events Event AmBisome [0m[1;31m3[0m[31m mg/kg/day N = [0m[1;31m343[0m[31m Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day N = [0m[1;31m344[0m[31m [0m
[31mHypotension [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m3.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m8.1[0m[31m%[0m[1;31m)[0m[31m Tachycardia [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m11.3[0m[31m%[0m[1;31m)[0m[31m Vasodilatation [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m5.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.6[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m7.3[0m[31m%[0m[1;31m)[0m[31m Hyperventilation [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m4.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mHypoxia [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m%[0m[1;31m)[0m[31m The percentage of patients who received drugs either for the treatment or prevention of infusion-related reactions [0m[1;31m([0m[31me.g., acetaminophen, [0m
[31mdiphenhydramine, meperidine and hydrocortisone[0m[1;31m)[0m[31m was lower in Am B isome-treated patients compared with amphotericin B deoxycholate-treated patients. In the empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, on Day [0m[1;31m1[0m[31m, [0m
[31mwhere no premedication was administered, the overall incidence of infusion-related events of chills/rigors was significantly lower for patients administered Am B isome compared with amphotericin B [0m
[31mlipid complex. Fever, chills/rigors and hypoxia were significantly lower for each Am B isome group compared with the amphotericin B lipid complex group. The infusion-related event hypoxia was reported[0m
[31mfor [0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m% of amphotericin B lipid complex-treated patients compared with [0m[1;31m0[0m[31m% of patients administered [0m[1;31m3[0m[31m mg/kg per day Am B isome and [0m[1;31m1.2[0m[31m% of patients treated with [0m[1;31m5[0m[31m mg/kg [0m
[31mper day Am B isome. Incidence of Day [0m[1;31m1[0m[31m Infusion-Related Reactions [0m[1;31m([0m[31mIRR[0m[1;31m)[0m[31m Chills/Rigors Empirical Therapy Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH [0m
[31mTotal number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Patients with Chills/Rigors [0m[1;31m([0m[31mDay [0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m23.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m21.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m62[0m[31m [0m[1;31m([0m[1;31m79.5[0m[31m%[0m[1;31m)[0m[31m Patients with other notable reactions: Fever [0m[1;31m([0m[31m [0m[1;31m>[0m[31m [0m[1;31m1.0[0m[31m o C increase in temperature[0m[1;31m)[0m[31m [0m
[1;31m20[0m[31m [0m[1;31m([0m[1;31m23.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m19.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m36[0m[31m [0m[1;31m([0m[1;31m21[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-9.4[0m[31m%, +[0m[1;31m31[0m[31m% [0m[1;31m36[0m[31m/[0m[1;31m75[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-18.8[0m[31m%, +[0m[1;31m19.8[0m[31m% [0m[1;31m29[0m[31m/[0m[1;31m61[0m[31m [0m[1;31m([0m[1;31m47.5[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m97.5[0m[31m% Confidence Interval for the difference between Am B isome and amphotericin[0m
[31mB success rates. A negative value is in favor of amphotericin B. A positive value is in favor of Am B isome. Success at [0m[1;31m10[0m[31m weeks was defined as clinical success at week [0m[1;31m10[0m[31m plus CSF culture conversion [0m
[31mat or prior to week [0m[1;31m10[0m[31m. Success rates at [0m[1;31m10[0m[31m weeks in patients with positive baseline culture for cryptococcus species are summarized in the following table and show that the efficacy of Am B isome [0m[1;31m6[0m[31m [0m
[31mmg/kg/day approximates the efficacy of the amphotericin B deoxycholate regimen. AMBISOME: clinical_studies: These data do not support the conclusion that Am B isome [0m[1;31m3[0m[31m mg/kg/day is comparable in [0m
[31mefficacy to amphotericin B deoxycholate. The table also presents [0m[1;31m10[0m[31m-week survival rates for patients treated in this study. Success Rates and Survival Rates at Week [0m[1;31m10[0m[31m, Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m [0m[1;31m([0m[31msee text for [0m
[31mdefinitions[0m[1;31m)[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.7[0m[31m mg/kg/day Success in patients with documented cryptococcal meningitis [0m[1;31m27[0m[31m/[0m[1;31m73[0m[31m [0m[1;31m([0m[1;31m37[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-33.7[0m[31m%, +[0m[1;31m2.4[0m[31m% [0m[1;31m42[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m49[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% [0m
[31mCI* = [0m[1;31m-20.9[0m[31m%, +[0m[1;31m14.5[0m[31m% [0m[1;31m40[0m[31m/[0m[1;31m76[0m[31m [0m[1;31m([0m[1;31m53[0m[31m%[0m[1;31m)[0m[31m Survival rates [0m[1;31m74[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m86[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-13.8[0m[31m%, +[0m[1;31m8[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m% [0m[1;31m85[0m[31m/[0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m90[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-8.3[0m[31m%, +[0m[1;31m12.2[0m[31m% [0m[1;31m77[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m89[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m97.5[0m[31m% Confidence Interval for the[0m
[31mdifference between Am B isome and amphotericin B rates. A negative value is in favor of amphotericin B. A positive value is in favor of Am B isome. The incidence of infusion-related, cardiovascular [0m
[31mand renal adverse events was lower in patients receiving Am B isome compared to amphotericin B deoxycholate [0m[1;31m([0m[31msee ADVERSE REACTIONS section for details[0m[1;31m)[0m[31m; therefore, the risks and benefits [0m[1;31m([0m[31madvantages [0m
[31mand disadvantages[0m[1;31m)[0m[31m of the different amphotericin B formulations should be taken into consideration when selecting a patient treatment regimen. AMBISOME: clinical_studies: Treatment of Patients with [0m
[31mAspergillus Species, Candida Species and/or Cryptococcus Species Infections Refractory to Amphotericin B Deoxycholate, or in Patients Where Renal Impairment or Unacceptable Toxicity Precludes the Use [0m
[31mof Amphotericin B Deoxycholate Am B isome was evaluated in a compassionate use study in hospitalized patients with systemic fungal infections. These patients either had fungal infections refractory to[0m
[31mamphotericin B deoxycholate, were intolerant to the use of amphotericin B deoxycholate, or had pre-existing renal insufficiency. Patient recruitment involved [0m[1;31m140[0m[31m infectious episodes in [0m[1;31m133[0m[31m patients, [0m
[31mwith [0m[1;31m53[0m[31m episodes evaluable for mycological response and [0m[1;31m91[0m[31m episodes evaluable for clinical outcome. Clinical success and mycological eradication occurred in some patients with documented [0m
[31maspergillosis, candidiasis, and cryptococcosis. AMBISOME: clinical_studies: Treatment of Visceral Leishmaniasis Am B isome was studied in patients with visceral leishmaniasis who were infected in the [0m
[31mMediterranean basin with documented or presumed Leishmania infantum . Clinical studies have not provided conclusive data regarding efficacy against L. donovani or L. chagasi . Am B isome achieved high[0m
[31mrates of acute parasite clearance in immunocompetent patients when total doses of [0m[1;31m12[0m[31m-[0m[1;31m30[0m[31m mg/kg were administered. Most of these immunocompetent patients remained relapse-free during follow-up periods [0m
[31mof [0m[1;31m6[0m[31m months or longer. While acute parasite clearance was achieved in most of the immunocompromised patients who received total doses of [0m[1;31m30[0m[31m-[0m[1;31m40[0m[31m mg/kg, the majority of these patients were observed to [0m
[31mrelapse in the [0m[1;31m6[0m[31m months following the completion of therapy. Of the [0m[1;31m21[0m[31m immunocompromised patients studied, [0m[1;31m17[0m[31m were coinfected with HIV; approximately half of the HIV-infected patients had AIDS.       [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMBISOME"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does AMBISOME increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of [0m
[32mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMBISOME"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: AMBISOME: clinical_studies: The following table presents a comparison of efficacy rates among immunocompetent and immunocompromised patients infected in the Mediterranean basin who had no [0m
[31mprior treatment or remote prior treatment for visceral leishmaniasis. Efficacy is expressed as both acute parasite clearance at the end of therapy [0m[1;31m([0m[31mEOT[0m[1;31m)[0m[31m and as overall success [0m[1;31m([0m[31mclearance with no [0m
[31mrelapse[0m[1;31m)[0m[31m during the follow-up period [0m[1;31m([0m[31mF/U[0m[1;31m)[0m[31m of greater than [0m[1;31m6[0m[31m months for immunocompetent and immunocompromised patients: AmBisome Efficacy in Visceral Leishmaniasis Immunocompetent Patients No. of [0m
[31mPatients Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m[1;31m87[0m[31m [0m[1;31m86[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m98.9[0m[1;31m)[0m[31m [0m[1;31m83[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m96.5[0m[1;31m)[0m[31m Immunocompromised Patients Regimen Total Dose Parasite [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m Clearance at EOT Overall Success [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m at F/U [0m
[1;31m100[0m[31m mg/day X [0m[1;31m21[0m[31m days [0m[1;31m29[0m[31m-[0m[1;31m38[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m mg/kg [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m20[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m mg/kg/day, days [0m[1;31m1[0m[31m-[0m[1;31m5[0m[31m, and [0m[1;31m10[0m[31m, [0m[1;31m17[0m[31m, [0m[1;31m24[0m[31m, [0m[1;31m31[0m[31m, [0m[1;31m38[0m[31m [0m[1;31m40[0m[31m mg/kg [0m[1;31m8[0m[31m/[0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m88.9[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m/[0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m0[0m[1;31m)[0m[31m TOTAL [0m[1;31m18[0m[31m/[0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m94.7[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m/[0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m11.8[0m[1;31m)[0m[31m When [0m
[31mfollowed for [0m[1;31m6[0m[31m months or more after treatment, the overall success rate among immunocompetent patients was [0m[1;31m96.5[0m[31m% and the overall success rate among immunocompromised patients was [0m[1;31m11.8[0m[31m% due to relapse [0m
[31min the majority of patients. While case reports have suggested there may be a role for long-term therapy to prevent relapses in HIV coinfected patients [0m[1;31m([0m[31mLopez-Dupla, et al. AMBISOME: clinical_studies:[0m
[31mJ Antimicrob Chemother [0m[1;31m1993[0m[31m; [0m[1;31m32[0m[31m: [0m[1;31m657[0m[31m-[0m[1;31m659[0m[1;31m)[0m[31m, there are no data to date documenting the efficacy or safety of repeat courses of Am B isome or of maintenance therapy with this drug among immunocompromised[0m
[31mpatients.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m Fever resolution during neutropenic period [0m[1;31m199[0m[31m [0m[1;31m([0m[1;31m58[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m200[0m[31m [0m[1;31m([0m[1;31m58.1[0m[31m%[0m[1;31m)[0m[31m No treatment-emergent fungal infection [0m[1;31m300[0m[31m [0m[1;31m([0m[1;31m87.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m301[0m[31m [0m[1;31m([0m[1;31m87.7[0m[31m%[0m[1;31m)[0m[31m Survival through [0m[1;31m7[0m[31m days post [0m
[31mstudy drug [0m[1;31m318[0m[31m [0m[1;31m([0m[1;31m92.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m308[0m[31m [0m[1;31m([0m[1;31m89.5[0m[31m%[0m[1;31m)[0m[31m Study drug not prematurely discontinued due to toxicity or lack of efficacy* [0m[1;31m294[0m[31m [0m[1;31m([0m[1;31m85.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m280[0m[31m [0m[1;31m([0m[1;31m81.4[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m8[0m[31m and [0m[1;31m10[0m[31m patients, respectively, were treated as failures due [0m
[31mto premature discontinuation alone. This therapeutic equivalence had no apparent relationship to the use of prestudy antifungal prophylaxis or concomitant granulocytic colony-stimulating factors. The [0m
[31mincidence of mycologically-confirmed, and clinically-diagnosed, emergent fungal infections are presented in the following table. Am B isome and amphotericin B were found to be equivalent with respect [0m
[31mto the total number of emergent fungal infections. AMBISOME: clinical_studies: Empirical Therapy in Febrile Neutropenic Patients: Emergent Fungal Infections AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m [0m
[31mmg/kg/day Number of patients receiving at least one dose of study drug [0m[1;31m343[0m[31m [0m[1;31m344[0m[31m Mycologically-confirmed fungal infection [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m3.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m27[0m[31m [0m[1;31m([0m[1;31m7.8[0m[31m%[0m[1;31m)[0m[31m Clinically-diagnosed fungal infection [0m[1;31m32[0m[31m [0m[1;31m([0m[1;31m9.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTotal emergent fungal infections [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m Mycologically-confirmed fungal infections at study entry were cured in [0m[1;31m8[0m[31m of [0m[1;31m11[0m[31m patients in the Am B isome group and [0m[1;31m7[0m[31m of [0m[1;31m10[0m[31m in the amphotericin B[0m
[31mgroup. AMBISOME: clinical_studies: Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a randomized, double-blind, comparative multi-center trial, evaluated the safety of Am B isome [0m[1;31m([0m[1;31m3[0m[31m and [0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m compared with amphotericin B lipid[0m
[31mcomplex [0m[1;31m([0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m in the empirical treatment of [0m[1;31m202[0m[31m adult and [0m[1;31m42[0m[31m pediatric neutropenic patients. One hundred and sixty-six [0m[1;31m([0m[1;31m166[0m[1;31m)[0m[31m patients received Am B isome [0m[1;31m([0m[1;31m85[0m[31m patients received [0m[1;31m3[0m[31m mg/kg/day and [0m
[1;31m81[0m[31m received [0m[1;31m5[0m[31m mg/kg/day[0m[1;31m)[0m[31m and [0m[1;31m78[0m[31m patients received amphotericin B lipid complex. The study patients were febrile despite having received at least [0m[1;31m72[0m[31m hours of broad spectrum antibacterial therapy. The [0m
[31mprimary endpoint of this study was safety. The study was not designed to draw statistically meaningful conclusions related to comparative efficacy and, in fact, Abelcet is not labeled for this [0m
[31mindication. AMBISOME: clinical_studies: Two supportive, prospective, randomized, open-label, comparative multi-center studies examined the efficacy of two dosages of Am B isome [0m[1;31m([0m[1;31m1[0m[31m and [0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m [0m
[31mcompared to amphotericin B deoxycholate [0m[1;31m([0m[1;31m1[0m[31m mg/kg/day[0m[1;31m)[0m[31m in the treatment of neutropenic patients with presumed fungal infections. These patients were undergoing chemotherapy as part of a bone marrow [0m
[31mtransplant or had hematological disease. Study [0m[1;31m104[0m[31m-[0m[1;31m10[0m[31m enrolled adult patients [0m[1;31m([0m[31mn = [0m[1;31m134[0m[1;31m)[0m[31m. Study [0m[1;31m104[0m[31m-[0m[1;31m14[0m[31m enrolled pediatric patients [0m[1;31m([0m[31mn = [0m[1;31m214[0m[1;31m)[0m[31m. Both studies support the efficacy equivalence of Am B isome[0m
[31mand amphotericin B as empirical therapy in febrile neutropenic patients. AMBISOME: clinical_studies: Treatment of Cryptococcal Meningitis in HIV-Infected Patients Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, [0m
[31mdouble-blind, comparative multi-center trial, evaluated the efficacy of Am B isome at doses [0m[1;31m([0m[1;31m3[0m[31m and [0m[1;31m6[0m[31m mg/kg/day[0m[1;31m)[0m[31m compared with amphotericin B deoxycholate [0m[1;31m([0m[1;31m0.7[0m[31m mg/kg/day[0m[1;31m)[0m[31m for the treatment of [0m
[31mcryptococcal meningitis in [0m[1;31m266[0m[31m adult and one pediatric HIV-positive patients [0m[1;31m([0m[31mthe pediatric patient received amphotericin B deoxycholate[0m[1;31m)[0m[31m. Of the [0m[1;31m267[0m[31m treated patients, [0m[1;31m86[0m[31m received Am B isome [0m[1;31m3[0m[31m [0m
[31mmg/kg/day, [0m[1;31m94[0m[31m received [0m[1;31m6[0m[31m mg/kg/day and [0m[1;31m87[0m[31m received amphotericin B deoxycholate; cryptococcal meningitis was documented by a positive CSF culture at baseline in [0m[1;31m73[0m[31m, [0m[1;31m85[0m[31m and [0m[1;31m76[0m[31m patients, respectively. [0m
[31mPatients received study drug once daily for an induction period of [0m[1;31m11[0m[31m to [0m[1;31m21[0m[31m days.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: [0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m57.7[0m[31m%[0m[1;31m)[0m[31m Nausea [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m10.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m9.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m Vomiting [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m5.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m14.1[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m8.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m15.4[0m[31m%[0m[1;31m)[0m[31m [0m
[31mTachycardia [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m17.9[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m7.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m10.3[0m[31m%[0m[1;31m)[0m[31m Hypoxia [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m9[0m[31m [0m[1;31m([0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m Day [0m[1;31m1[0m[31m body temperature increased [0m
[31mabove the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest infusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. Patients were not administered [0m
[31mpremedications to prevent infusion-related reactions prior to the Day [0m[1;31m1[0m[31m study drug infusion. In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m, a randomized, double-blind, multicenter trial comparing Am B isome and amphotericin B [0m
[31mdeoxycholate as initial therapy for cryptococcal meningitis, premedications to prevent infusion-related reactions were permitted. Am B isome-treated patients had a lower incidence of fever, [0m
[31mchills/rigors and respiratory adverse events as summarized in the following table: Incidence of Infusion-Related Reactions Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0[0m[31m. [0m
[31mAMBISOME: adverse_reactions: [0m[1;31m7[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m86[0m[31m [0m[1;31m94[0m[31m [0m[1;31m87[0m[31m Patients with fever increase of >[0m[1;31m1[0m[31m°C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mchills/rigors [0m[1;31m5[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m42[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m14[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m14[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m Respiratory adverse events [0m[1;31m0[0m[31m [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m There have been a few [0m
[31mreports of flushing, back pain with or without chest tightness, and chest pain associated with Am B isome administration; on occasion this has been severe. Where these symptoms were noted, the [0m
[31mreaction developed within a few minutes after the start of infusion and disappeared rapidly when the infusion was stopped. AMBISOME: adverse_reactions: The symptoms do not occur with every dose and [0m
[31musually do not recur on subsequent administrations when the infusion rate is slowed. Toxicity and Discontinuation of Dosing In Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m002[0m[31m, a significantly lower incidence of grade [0m[1;31m3[0m[31m or [0m[1;31m4[0m[31m toxicity [0m
[31mwas observed in the Am B isome group compared with the amphotericin B group. In addition, nearly three times as many patients administered amphotericin B required a reduction in dose due to toxicity [0m
[31mor discontinuation of study drug due to an infusion-related reaction compared with those administered Am B isome. In empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, a greater proportion of patients in the [0m
[31mamphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Am B isome groups. AMBISOME: adverse_reactions: Less Common Adverse Events The following adverse [0m
[31mevents also have been reported in [0m[1;31m2[0m[31m% to [0m[1;31m10[0m[31m% of Am B isome-treated patients receiving chemotherapy or bone marrow transplantation, or who had HIV disease in six comparative, clinical trials: Body as a [0m
[31mWhole Abdomen enlarged, allergic reaction, cellulitis, cell-mediated immunological reaction, face edema, graft-versus-host disease, malaise, neck pain, and procedural complication. Cardiovascular [0m
[31mSystem Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder, and vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: adverse_reactions: Am B isome-treated patients had a lower incidence of infusion-related fever [0m[1;31m([0m[1;31m17[0m[31m% versus [0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m, chills/rigors [0m[1;31m([0m[1;31m18[0m[31m% versus [0m[1;31m54[0m[31m%[0m[1;31m)[0m[31m and vomiting [0m[1;31m([0m[1;31m6[0m[31m% versus [0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m on Day [0m[1;31m1[0m[31m [0m
[31mas compared to amphotericin B deoxycholate-treated patients. The incidence of infusion-related reactions on Day [0m[1;31m1[0m[31m in pediatric and adult patients is summarized in the following table: Incidence of Day[0m
[1;31m1[0m[31m Infusion-Related Reactions [0m[1;31m([0m[31mIRR[0m[1;31m)[0m[31m By Patient Age Pediatric Patients [0m[1;31m([0m[31m≤ [0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m Adult Patients [0m[1;31m([0m[31m> [0m[1;31m16[0m[31m years of age[0m[1;31m)[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day AmBisome [0m[1;31m3[0m[31m mg/kg/day [0m
[31mAmphotericin B [0m[1;31m0.6[0m[31m mg/kg/day Total number of patients receiving at least one dose of study drug [0m[1;31m48[0m[31m [0m[1;31m47[0m[31m [0m[1;31m295[0m[31m [0m[1;31m297[0m[31m Patients with fever* increase ≥ [0m[1;31m1[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m0[0m[31m o C [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m47[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m
[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m128[0m[31m [0m[1;31m([0m[1;31m43[0m[31m%[0m[1;31m)[0m[31m Patients with chills/rigors [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m47[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m59[0m[31m [0m[1;31m([0m[1;31m20[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m165[0m[31m [0m[1;31m([0m[1;31m56[0m[31m%[0m[1;31m)[0m[31m Patients with nausea [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m38[0m[31m [0m[1;31m([0m[1;31m13[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m31[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Patients with vomiting [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m21[0m[31m [0m[1;31m([0m[1;31m7[0m[31m%[0m[1;31m)[0m[31m Patients with [0m
[31mother reactions [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m21[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m13[0m[31m [0m[1;31m([0m[1;31m28[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m47[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m23[0m[31m%[0m[1;31m)[0m[31m * Day [0m[1;31m1[0m[31m body temperature increased above the temperature taken within [0m[1;31m1[0m[31m hour prior to infusion [0m[1;31m([0m[31mpreinfusion temperature[0m[1;31m)[0m[31m or above the lowest [0m
[31minfusion value [0m[1;31m([0m[31mno preinfusion temperature recorded[0m[1;31m)[0m[31m. AMBISOME: adverse_reactions: Cardiorespiratory events, except for vasodilatation [0m[1;31m([0m[31mflushing[0m[1;31m)[0m[31m, during all study drug infusions were more frequent in[0m
[31mamphotericin B-treated patients as summarized in the following table: Incidence of Infusion-Related Cardiorespiratory Events Event AmBisome [0m[1;31m3[0m[31m mg/kg/day N = [0m[1;31m343[0m[31m Amphotericin B [0m[1;31m0.6[0m[31m mg/kg/day N = [0m[1;31m344[0m[31m [0m
[31mHypotension [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m3.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m8.1[0m[31m%[0m[1;31m)[0m[31m Tachycardia [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m12.5[0m[31m%[0m[1;31m)[0m[31m Hypertension [0m[1;31m8[0m[31m [0m[1;31m([0m[1;31m2.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m11.3[0m[31m%[0m[1;31m)[0m[31m Vasodilatation [0m[1;31m18[0m[31m [0m[1;31m([0m[1;31m5.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.6[0m[31m%[0m[1;31m)[0m[31m Dyspnea [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m4.7[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m25[0m[31m [0m[1;31m([0m[1;31m7.3[0m[31m%[0m[1;31m)[0m[31m Hyperventilation [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m17[0m[31m [0m[1;31m([0m[1;31m4.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mHypoxia [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[1;31m6.4[0m[31m%[0m[1;31m)[0m[31m The percentage of patients who received drugs either for the treatment or prevention of infusion-related reactions [0m[1;31m([0m[31me.g., acetaminophen, [0m
[31mdiphenhydramine, meperidine and hydrocortisone[0m[1;31m)[0m[31m was lower in Am B isome-treated patients compared with amphotericin B deoxycholate-treated patients. In the empirical therapy study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m, on Day [0m[1;31m1[0m[31m, [0m
[31mwhere no premedication was administered, the overall incidence of infusion-related events of chills/rigors was significantly lower for patients administered Am B isome compared with amphotericin B [0m
[31mlipid complex. Fever, chills/rigors and hypoxia were significantly lower for each Am B isome group compared with the amphotericin B lipid complex group. The infusion-related event hypoxia was reported[0m
[31mfor [0m[1;31m11[0m[31m. AMBISOME: adverse_reactions: [0m[1;31m5[0m[31m% of amphotericin B lipid complex-treated patients compared with [0m[1;31m0[0m[31m% of patients administered [0m[1;31m3[0m[31m mg/kg per day Am B isome and [0m[1;31m1.2[0m[31m% of patients treated with [0m[1;31m5[0m[31m mg/kg [0m
[31mper day Am B isome. Incidence of Day [0m[1;31m1[0m[31m Infusion-Related Reactions [0m[1;31m([0m[31mIRR[0m[1;31m)[0m[31m Chills/Rigors Empirical Therapy Study [0m[1;31m97[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m034[0m[31m AmBisome Amphotericin B lipid complex [0m[1;31m5[0m[31m mg/kg/day [0m[1;31m3[0m[31m mg/kg/day [0m[1;31m5[0m[31m mg/kg/day BOTH [0m
[31mTotal number of patients [0m[1;31m85[0m[31m [0m[1;31m81[0m[31m [0m[1;31m166[0m[31m [0m[1;31m78[0m[31m Patients with Chills/Rigors [0m[1;31m([0m[31mDay [0m[1;31m1[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m18.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m19[0m[31m [0m[1;31m([0m[1;31m23.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m21.1[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m62[0m[31m [0m[1;31m([0m[1;31m79.5[0m[31m%[0m[1;31m)[0m[31m Patients with other notable reactions: Fever [0m[1;31m([0m[31m [0m[1;31m>[0m[31m [0m[1;31m1.0[0m[31m o C increase in temperature[0m[1;31m)[0m[31m [0m
[1;31m20[0m[31m [0m[1;31m([0m[1;31m23.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m19.8[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m36[0m[31m [0m[1;31m([0m[1;31m21[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m


[31mCONTENT: AMBISOME: clinical_studies: [0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-9.4[0m[31m%, +[0m[1;31m31[0m[31m% [0m[1;31m36[0m[31m/[0m[1;31m75[0m[31m [0m[1;31m([0m[1;31m48[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-18.8[0m[31m%, +[0m[1;31m19.8[0m[31m% [0m[1;31m29[0m[31m/[0m[1;31m61[0m[31m [0m[1;31m([0m[1;31m47.5[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m97.5[0m[31m% Confidence Interval for the difference between Am B isome and amphotericin[0m
[31mB success rates. A negative value is in favor of amphotericin B. A positive value is in favor of Am B isome. Success at [0m[1;31m10[0m[31m weeks was defined as clinical success at week [0m[1;31m10[0m[31m plus CSF culture conversion [0m
[31mat or prior to week [0m[1;31m10[0m[31m. Success rates at [0m[1;31m10[0m[31m weeks in patients with positive baseline culture for cryptococcus species are summarized in the following table and show that the efficacy of Am B isome [0m[1;31m6[0m[31m [0m
[31mmg/kg/day approximates the efficacy of the amphotericin B deoxycholate regimen. AMBISOME: clinical_studies: These data do not support the conclusion that Am B isome [0m[1;31m3[0m[31m mg/kg/day is comparable in [0m
[31mefficacy to amphotericin B deoxycholate. The table also presents [0m[1;31m10[0m[31m-week survival rates for patients treated in this study. Success Rates and Survival Rates at Week [0m[1;31m10[0m[31m, Study [0m[1;31m94[0m[31m-[0m[1;31m0[0m[31m-[0m[1;31m013[0m[31m [0m[1;31m([0m[31msee text for [0m
[31mdefinitions[0m[1;31m)[0m[31m AmBisome [0m[1;31m3[0m[31m mg/kg/day AmBisome [0m[1;31m6[0m[31m mg/kg/day Amphotericin B [0m[1;31m0.7[0m[31m mg/kg/day Success in patients with documented cryptococcal meningitis [0m[1;31m27[0m[31m/[0m[1;31m73[0m[31m [0m[1;31m([0m[1;31m37[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-33.7[0m[31m%, +[0m[1;31m2.4[0m[31m% [0m[1;31m42[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m49[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% [0m
[31mCI* = [0m[1;31m-20.9[0m[31m%, +[0m[1;31m14.5[0m[31m% [0m[1;31m40[0m[31m/[0m[1;31m76[0m[31m [0m[1;31m([0m[1;31m53[0m[31m%[0m[1;31m)[0m[31m Survival rates [0m[1;31m74[0m[31m/[0m[1;31m86[0m[31m [0m[1;31m([0m[1;31m86[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-13.8[0m[31m%, +[0m[1;31m8[0m[31m. AMBISOME: clinical_studies: [0m[1;31m9[0m[31m% [0m[1;31m85[0m[31m/[0m[1;31m94[0m[31m [0m[1;31m([0m[1;31m90[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m97.5[0m[31m% CI* = [0m[1;31m-8.3[0m[31m%, +[0m[1;31m12.2[0m[31m% [0m[1;31m77[0m[31m/[0m[1;31m87[0m[31m [0m[1;31m([0m[1;31m89[0m[31m%[0m[1;31m)[0m[31m * [0m[1;31m97.5[0m[31m% Confidence Interval for the[0m
[31mdifference between Am B isome and amphotericin B rates. A negative value is in favor of amphotericin B. A positive value is in favor of Am B isome. The incidence of infusion-related, cardiovascular [0m
[31mand renal adverse events was lower in patients receiving Am B isome compared to amphotericin B deoxycholate [0m[1;31m([0m[31msee ADVERSE REACTIONS section for details[0m[1;31m)[0m[31m; therefore, the risks and benefits [0m[1;31m([0m[31madvantages [0m
[31mand disadvantages[0m[1;31m)[0m[31m of the different amphotericin B formulations should be taken into consideration when selecting a patient treatment regimen. AMBISOME: clinical_studies: Treatment of Patients with [0m
[31mAspergillus Species, Candida Species and/or Cryptococcus Species Infections Refractory to Amphotericin B Deoxycholate, or in Patients Where Renal Impairment or Unacceptable Toxicity Precludes the Use [0m
[31mof Amphotericin B Deoxycholate Am B isome was evaluated in a compassionate use study in hospitalized patients with systemic fungal infections. These patients either had fungal infections refractory to[0m
[31mamphotericin B deoxycholate, were intolerant to the use of amphotericin B deoxycholate, or had pre-existing renal insufficiency. Patient recruitment involved [0m[1;31m140[0m[31m infectious episodes in [0m[1;31m133[0m[31m patients, [0m
[31mwith [0m[1;31m53[0m[31m episodes evaluable for mycological response and [0m[1;31m91[0m[31m episodes evaluable for clinical outcome. Clinical success and mycological eradication occurred in some patients with documented [0m
[31maspergillosis, candidiasis, and cryptococcosis. AMBISOME: clinical_studies: Treatment of Visceral Leishmaniasis Am B isome was studied in patients with visceral leishmaniasis who were infected in the [0m
[31mMediterranean basin with documented or presumed Leishmania infantum . Clinical studies have not provided conclusive data regarding efficacy against L. donovani or L. chagasi . Am B isome achieved high[0m
[31mrates of acute parasite clearance in immunocompetent patients when total doses of [0m[1;31m12[0m[31m-[0m[1;31m30[0m[31m mg/kg were administered. Most of these immunocompetent patients remained relapse-free during follow-up periods [0m
[31mof [0m[1;31m6[0m[31m months or longer. While acute parasite clearance was achieved in most of the immunocompromised patients who received total doses of [0m[1;31m30[0m[31m-[0m[1;31m40[0m[31m mg/kg, the majority of these patients were observed to [0m
[31mrelapse in the [0m[1;31m6[0m[31m months following the completion of therapy. Of the [0m[1;31m21[0m[31m immunocompromised patients studied, [0m[1;31m17[0m[31m were coinfected with HIV; approximately half of the HIV-infected patients had AIDS.       [0m
[31mSOUR[0m[1;31mCE:A[0m[31mMBISOME label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes AMBISOME increase or decrease the risk of [0m
[32mmortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes AMBISOME increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"AMBISOME"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does AMBISOME increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether AMBISOME increases or decreases the risk of mortality after myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether AMBISOME increases or decreases the risk of mortality after myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether AMBISOME increases or decreases the risk of mortality after myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided does not explain why the information is not available. The final answer of DO-NOT-KNOW is acceptable only if it is accompanied by a clear explanation of why it [0m
[32mwas not possible to answer the question. The user should have provided the reason, such as lack of data, lack of studies, or any other specific reason that FDAHandler may have given for not having the[0m
[32minformation."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided does not explain why the information is not available. The final answer of DO-NOT-KNOW is acceptable only if it is accompanied by a clear explanation of why it [0m
[34mwas not possible to answer the question. The user should have provided the reason, such as lack of data, lack of studies, or any other specific reason that FDAHandler may have given for not having the[0m
[34minformation."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided does not explain why the information is not available. The final answer of DO-NOT-KNOW is acceptable only if it is accompanied by a clear explanation of why it[0m
[31mwas not possible to answer the question. The user should have provided the reason, such as lack of data, lack of studies, or any other specific reason that FDAHandler may have given for not having the[0m
[31minformation.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mI apologize for the oversight. Let me clarify the [0m
[32mreasoning behind the DO-NOT-KNOW answer.[0m

[32mThe question asked was whether AMBISOME increases or decreases the risk of mortality after myocardial infarction. To answer this question, I reached out to FDAHandler for information regarding [0m
[32mAMBISOME and its effects on mortality post-myocardial infarction. However, FDAHandler did not provide any information that could answer this question. This could be due to a lack of specific data or [0m
[32mstudies on the subject within the FDA label data, or because the effect of AMBISOME on mortality after myocardial infarction is not a documented or known side effect or indication.[0m

[32mTherefore, without specific information from FDA label data, I cannot provide a reliable answer to whether AMBISOME increases or decreases the risk of mortality after myocardial infarction. Hence, the[0m
[32mfinal answer is DO-NOT-KNOW.[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I attempted to ask FDAHandler whether AMBISOME increases or decreases the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler did not provide any information that could answer this question."[0m[32m,[0m
[32m      [0m[32m"The lack of information could be due to the absence of data or studies on the subject within the FDA label data, or because the effect of AMBISOME on mortality after myocardial infarction is [0m
[32mnot a documented or known side effect or indication."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I attempted to ask FDAHandler whether AMBISOME increases or decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler did not provide any information that could answer this question."[0m[34m,[0m
[34m      [0m[34m"The lack of information could be due to the absence of data or studies on the subject within the FDA label data, or because the effect of AMBISOME on mortality after myocardial infarction is [0m
[34mnot a documented or known side effect or indication."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does AMBISOME increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I attempted to ask FDAHandler whether AMBISOME increases or decreases the risk of mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler did not provide any information that could answer this question.[0m
[1;31m3[0m[31m. The lack of information could be due to the absence of data or studies on the subject within the FDA label data, or because the effect of AMBISOME on mortality after myocardial infarction is not a [0m
[31mdocumented or known side effect or indication.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-AMBISOME[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe final answer to the question of whether AMBISOME increases or decreases the risk of mortality after myocardial infarction is DO-NOT-KNOW. This is because FDAHandler did not provide any information[0m
[32mthat could answer this question, which could be due to a lack of specific data or studies on the subject within the FDA label data, or because the effect of AMBISOME on mortality after myocardial [0m
[32minfarction is not a documented or known side effect or indication. Without specific information from FDA label data, it is not possible to provide a reliable answer.[0m
